Quick Answer
Aldeyra Therapeutics, Inc. reported Net Income of -$33.85 million for fiscal year 2025.
Aldeyra Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$33.85M +39.4% |
-$55.85M -48.8% |
-$37.54M +39.5% |
-$62.02M -7.4% |
-$57.78M -53.8% |
-$37.55M +38.3% |
| Diluted EPS | -$0.56 +40.4% |
-$0.94 -46.9% |
-$0.64 +39.6% |
-$1.06 +0.9% |
-$1.07 | — |
| Total Assets | $72.06M -31.1% |
$104.61M -29.5% |
$148.33M -18.2% |
$181.29M -22.2% |
$233.14M +179.7% |
$83.35M +10.4% |
| Cash and Equivalents | — | — | — | — | — | — |
| Long-Term Debt | $0.00 -100.0% |
$15.00M | $0.00 -100.0% |
$14.92M -3.7% |
$15.50M +35.6% |
$11.43M -21.3% |
| Stockholders Equity | $44.25M -37.7% |
$71.00M -40.7% |
$119.80M -20.7% |
$151.01M -26.6% |
$205.74M +245.7% |
$59.51M +23.8% |
| R&D Expense | $25.66M -46.8% |
$48.22M +63.7% |
$29.46M -37.7% |
$47.31M +5.3% |
$44.94M +82.1% |
$24.68M -44.4% |
| Operating Income | -$35.27M +41.3% |
-$60.12M -40.5% |
-$42.79M +31.7% |
-$62.68M -11.5% |
-$56.22M -54.4% |
-$36.42M +42.3% |
| Shares Outstanding | 60.16M +0.9% |
59.65M +0.8% |
59.20M +1.1% |
58.56M +0.8% |
58.08M +50.2% |
38.67M +34.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$7.69M | +49.1% | +21.3% |
| Diluted EPS | September 30, 2025 | -$0.13 | +48.0% | +18.8% |
| Total Assets | September 30, 2025 | $77.80M | -33.7% | -8.4% |
| Cash and Equivalents | June 30, 2019 | $39.40M | +60.1% | -11.1% |
| Long-Term Debt | September 30, 2025 | $0.00 | -100.0% | — |
| Stockholders Equity | September 30, 2025 | $49.24M | -42.1% | -10.9% |
| R&D Expense | September 30, 2025 | $5.43M | -56.3% | -36.1% |
| Operating Income | September 30, 2025 | -$8.00M | +50.4% | +21.3% |
| Shares Outstanding | September 30, 2025 | 60.16M | +1.0% | +0.2% |
- Aldeyra Therapeutics, Inc. reported Net Income of -$33.85 million for fiscal year 2025.
- Aldeyra Therapeutics, Inc. showed an increase of +39.4% in Net Income compared to the prior fiscal year.
- Aldeyra Therapeutics, Inc. reported Diluted EPS of $0.56 per share (loss) for fiscal year 2025.
- Aldeyra Therapeutics, Inc. showed an increase of +40.4% in Diluted EPS compared to the prior fiscal year.
- Aldeyra Therapeutics, Inc. reported Total Assets of $72.06 million for fiscal year 2025.
- Aldeyra Therapeutics, Inc. showed a decrease of -31.1% in Total Assets compared to the prior fiscal year.
- Aldeyra Therapeutics, Inc. reported Cash and Equivalents of $47.36 million for fiscal year 2018.
- Aldeyra Therapeutics, Inc. showed an increase of +136.5% in Cash and Equivalents compared to the prior fiscal year.
- Aldeyra Therapeutics, Inc. reported Long-Term Debt of $0.00 for fiscal year 2025.
- Aldeyra Therapeutics, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Aldeyra Therapeutics, Inc. reported Stockholders Equity of $44.25 million for fiscal year 2025.
- Aldeyra Therapeutics, Inc. showed a decrease of -37.7% in Stockholders Equity compared to the prior fiscal year.
- Aldeyra Therapeutics, Inc. reported R&D Expense of $25.66 million for fiscal year 2025.
- Aldeyra Therapeutics, Inc. showed a decrease of -46.8% in R&D Expense compared to the prior fiscal year.
- Aldeyra Therapeutics, Inc. reported Operating Income of -$35.27 million for fiscal year 2025.
- Aldeyra Therapeutics, Inc. showed an increase of +41.3% in Operating Income compared to the prior fiscal year.
- Aldeyra Therapeutics, Inc. reported Shares Outstanding of 60.16 million shares for fiscal year 2025.
- Aldeyra Therapeutics, Inc. showed an increase of +0.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: